We are live on ! Find out more
SRDX

Surmodics

Delisted

SRDX was delisted on the 18th of November, 2025.

111 hedge funds and large institutions have $274M invested in Surmodics in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 34

0.26% more ownership

Funds ownership: 85.49%85.75% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

4% less funds holding

Funds holding: 116111 (-5)

5% less capital invested

Capital invested by funds: $288M → $274M (-$14.5M)

43% less call options, than puts

Call options by funds: $491K | Put options by funds: $864K

Holders
111
Holders Change
-5
Holders Change %
-4.31%
% of All Funds
2.75%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
40
Reduced
34
Closed
10
Calls
$491K
Puts
$864K
Net Calls
-$373K
Net Calls Change
-$202K

SRDX Hedge Fund Activity: Q1 2017 in Review

111 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Surmodics (SRDX) for Q1 2017, worth a combined $274M — down 5% from $288M a quarter earlier.

Fund positioning in SRDX was balanced in Q1 2017: 10 funds opened new positions, 10 closed out, 40 added to existing stakes and 34 trimmed.

The largest buyer was BlackRock, adding an estimated $40.9M. The largest seller was JP Morgan Chase, cutting an estimated $5.84M.

  • 111 institutional investors held Surmodics (SRDX) as of Q1 2017, down from 116 in Q4 2016.
  • Funds reported $274M of Surmodics stock for Q1 2017, down 5% quarter-over-quarter.
  • 10 funds opened new Surmodics positions in Q1 2017 and 10 closed out, a net change of 0 holders.
  • The largest Surmodics buyer in Q1 2017 was BlackRock, an estimated $40.9M added.
  • The largest Surmodics seller in Q1 2017 was JP Morgan Chase, an estimated $5.84M sold.

Based on aggregated 13F filings for Q1 2017.